Goldstein E J, Citron D M, Bendon L, Vagvolgyi A E, Trousdale M D, Appleman M D
Arch Ophthalmol. 1987 Jul;105(7):991-4. doi: 10.1001/archopht.1987.01060070135043.
Norfloxacin, a new fluoroquinolone antibiotic related to nalidixic acid, was evaluated as a topical agent for clinical efficacy in bacterial eye infections. This study reports on the comparative in vitro activity of norfloxacin and ten topical antibiotics (nalidixic acid, polymyxin B, colistin, bacitracin, chloramphenicol, sulfamethoxazole, tetracycline, erythromycin, gentamicin, and tobramycin) against 203 pathogenic eye isolates of 17 genera (37 species). In general, norfloxacin had the greatest potency and broadest spectrum of activity of the agents tested. It was active against Staphylococcus aureus (minimal inhibitory concentration against 90% [MIC90], less than or equal to 1.0 microgram/mL), coagulase-negative staphylococci (MIC90, less than or equal to 1.0 microgram/mL), Pseudomonas aeruginosa (MIC90, less than or equal to 1.0 microgram/mL), and Haemophilus organisms (MIC90, less than or equal to 1.0 microgram/mL).
诺氟沙星是一种与萘啶酸相关的新型氟喹诺酮类抗生素，作为一种局部用药对细菌性眼部感染的临床疗效进行了评估。本研究报告了诺氟沙星与十种局部用抗生素（萘啶酸、多粘菌素B、黏菌素、杆菌肽、氯霉素、磺胺甲恶唑、四环素、红霉素、庆大霉素和妥布霉素）对17个属（37个种）的203株眼部致病分离菌株的体外活性比较。总体而言，诺氟沙星在所测试的药物中具有最强的效力和最广的活性谱。它对金黄色葡萄球菌（90%的最低抑菌浓度[MIC90]，小于或等于1.0微克/毫升）、凝固酶阴性葡萄球菌（MIC90，小于或等于1.0微克/毫升）、铜绿假单胞菌（MIC90，小于或等于1.0微克/毫升）和嗜血杆菌属微生物（MIC90，小于或等于1.0微克/毫升）均有活性。
